Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8ZFS

Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with T0070907 and MRL24

8ZFS の概要
エントリーDOI10.2210/pdb8zfs/pdb
分子名称Peroxisome proliferator-activated receptor gamma, 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide, (2S)-2-(3-{[1-(4-METHOXYBENZOYL)-2-METHYL-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL]METHYL}PHENOXY)PROPANOIC ACID, ... (4 entities in total)
機能のキーワードnuclear receptors, tzds, drug design, therapeutic targets, transcription
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数2
化学式量合計64509.34
構造登録者
Shang, J.,Kojetin, D.J. (登録日: 2024-05-08, 公開日: 2024-08-07, 最終更新日: 2025-04-23)
主引用文献Shang, J.,Kojetin, D.J.
Unanticipated mechanisms of covalent inhibitor and synthetic ligand cobinding to PPAR gamma.
Elife, 13:-, 2024
Cited by
PubMed Abstract: Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor transcription factor that regulates gene expression programs in response to ligand binding. Endogenous and synthetic ligands, including covalent antagonist inhibitors GW9662 and T0070907, are thought to compete for the orthosteric pocket in the ligand-binding domain (LBD). However, we previously showed that synthetic PPARγ ligands can cooperatively cobind with and reposition a bound endogenous orthosteric ligand to an alternate site, synergistically regulating PPARγ structure and function (Shang et al., 2018). Here, we reveal the structural mechanism of cobinding between a synthetic covalent antagonist inhibitor with other synthetic ligands. Biochemical and NMR data show that covalent inhibitors weaken-but do not prevent-the binding of other ligands via an allosteric mechanism, rather than direct ligand clashing, by shifting the LBD ensemble toward a transcriptionally repressive conformation, which structurally clashes with orthosteric ligand binding. Crystal structures reveal different cobinding mechanisms including alternate site binding to unexpectedly adopting an orthosteric binding mode by altering the covalent inhibitor binding pose. Our findings highlight the significant flexibility of the PPARγ orthosteric pocket, its ability to accommodate multiple ligands, and demonstrate that GW9662 and T0070907 should not be used as chemical tools to inhibit ligand binding to PPARγ.
PubMed: 39556436
DOI: 10.7554/eLife.99782
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.56 Å)
構造検証レポート
Validation report summary of 8zfs
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon